{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:12:55Z","timestamp":1790298775244,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["EDCTP-TMA-SF-1946-VARSAF"],"award-info":[{"award-number":["EDCTP-TMA-SF-1946-VARSAF"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020098","name":"IMI","doi-asserted-by":"publisher","award":["116068"],"award-info":[{"award-number":["116068"]}],"id":[{"id":"10.13039\/100020098","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jinf.2024.106237","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T20:58:28Z","timestamp":1723064308000},"page":"106237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Replication, safety and immunogenicity of the vectored Ebola vaccine rVSV-\u0394G-ZEBOV-GP in a sub-Saharan African paediatric population: A randomised controlled, open-label trial in children aged 1-12 years living in Lambar\u00e9n\u00e9, Gabon"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2121-6631","authenticated-orcid":false,"given":"Ayodele","family":"Alabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kossiwa","family":"Kokou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saidou","family":"Mahmoudou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranmali","family":"Kavishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sravya S.","family":"Nakka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Rothenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fungai P.","family":"Musangomunei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2184-0060","authenticated-orcid":false,"given":"Bisola F.","family":"Olubiyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juste C.","family":"Bie-Ondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita L.","family":"Kabwende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thirumalaisamy P.","family":"Velavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donata","family":"Medaglini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5297-9108","authenticated-orcid":false,"given":"Helder I.","family":"Nakaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Engler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali M.","family":"Harandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7984-8669","authenticated-orcid":false,"given":"Claire-Anne","family":"Siegrist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Kremsner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selidji T.","family":"Agnandji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2024.106237_bib1","first-page":"247","article-title":"Ebola haemorrhagic fever in Sudan, 1976","volume":"56","author":"Deng","year":"1978","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.jinf.2024.106237_bib2","first-page":"271","article-title":"Ebola haemorrhagic fever in Zaire, 1976","volume":"56","author":"Burke","year":"1978","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.jinf.2024.106237_bib3","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(10)60667-8","article-title":"Ebola haemorrhagic fever","volume":"377","author":"Feldmann","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2024.106237_bib4","unstructured":"Outbreak History | Ebola | CDC. \u3008https:\/\/www.cdc.gov\/ebola\/outbreaks\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/vhf\/ebola\/history\/chronology.html\u3009 [Accessed June 24, 2024]."},{"key":"10.1016\/j.jinf.2024.106237_bib5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jiph.2023.10.020","article-title":"Case fatality rate for Ebola disease, 1976\u20132022: a meta-analysis of global data","volume":"17","author":"Izudi","year":"2024","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.jinf.2024.106237_bib6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.15585\/mmwr.su6503a2","article-title":"Overview, control strategies, and lessons learned in the CDC response to the 2014\u20132016 Ebola Epidemic","volume":"65","author":"Bell","year":"2019","journal-title":"MMWR Suppl"},{"key":"10.1016\/j.jinf.2024.106237_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2019.100009","article-title":"rVSVDELTAG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: standardized template with key considerations for a risk\/benefit assessment","volume":"1","author":"Monath","year":"2019","journal-title":"Vaccin X"},{"key":"10.1016\/j.jinf.2024.106237_bib8","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1535-6108(03)00241-1","article-title":"VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents","volume":"4","author":"Stojdl","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jinf.2024.106237_bib9","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1080\/21645515.2019.1649532","article-title":"Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens","volume":"15","author":"Fathi","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jinf.2024.106237_bib10","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.cmi.2023.08.026","article-title":"Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability","volume":"29","author":"Huttner","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jinf.2024.106237_bib11","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3201\/eid2806.212223","article-title":"Effect of recombinant vesicular stomatitis virus-Zaire Ebola virus vaccination on Ebola virus disease illness and death, Democratic Republic of the Congo","volume":"28","author":"Rupani","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jinf.2024.106237_bib12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2024.106237_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002402","article-title":"Safety and immunogenicity of rVSV\u0394G-ZEBOV-GP Ebola vaccine in adults and children in Lambar\u00e9n\u00e9, Gabon: a phase I randomised trial","volume":"14","author":"Agnandji","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.jinf.2024.106237_bib14","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1473-3099(21)00128-6","article-title":"Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial","volume":"22","author":"Afolabi","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2024.106237_bib15","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1473-3099(20)30019-0","article-title":"Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial","volume":"20","author":"Tapia","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2024.106237_bib16","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1473-3099(22)00594-1","article-title":"Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial","volume":"23","author":"Manno","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2024.106237_bib17","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/infdis\/jiac283","article-title":"Monitoring of adverse events in recipients of the 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign","volume":"227","author":"Nyombayire","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jinf.2024.106237_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003865","article-title":"Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: a randomised, placebo-controlled, multicentre Phase II clinical trial","volume":"19","author":"Anywaine","year":"2022","journal-title":"PLoS Med"},{"key":"10.1016\/j.jinf.2024.106237_bib19","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2200072","article-title":"Randomized trial of vaccines for Zaire Ebola virus disease","volume":"387","author":"PREVAC Study Team","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2024.106237_bib20","unstructured":"U.S. FDA Approves Merck\u2019s ERVEBO\u00ae (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older \u2013 Merck.com. \u3008https:\/\/www.merck.com\/news\/u-s-fda-approves-mercks-ervebo-ebola-zaire-vaccine-live-for-use-in-children-12-months-of-age-and-older\/\u3009 [Accessed Oct 5, 2023]."},{"key":"10.1016\/j.jinf.2024.106237_bib21","unstructured":"Ebola virus vaccines. \u3008https:\/\/www.who.int\/groups\/global-advisory-committee-on-vaccine-safety\/topics\/ebola-virus-vaccines\u3009 [Accessed June 25, 2024]."},{"key":"10.1016\/j.jinf.2024.106237_bib22","unstructured":"Extraordinary meeting of the Strategic Advisory Group of Experts on Immunization on Ebola vaccination, May 2024: conclusions and recommendations Final draft Full meeting report to be published in the WHO Weekly Epidemiological. \u3008www.who.int\/immunization\/interim_ebola_recommendations_feb_2019.pdf\u3009 [Accessed July 1, 2024]."},{"key":"10.1016\/j.jinf.2024.106237_bib23","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/cid\/ciad693","article-title":"Immunogenicity and vaccine shedding after 1 or 2 doses of rVSV\u0394G-ZEBOV-GP Ebola Vaccine (ERVEBO\u00ae): results from a phase 2, randomized, placebo-controlled trial in children and adults","volume":"78","author":"Lee","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2024.106237_bib24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.vaccine.2014.09.035","article-title":"The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)","volume":"33","author":"Chen","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2024.106237_bib25","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 trials of rVSV Ebola vaccine in Africa and Europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2024.106237_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003065","article-title":"Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus","volume":"8","author":"Mohan","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jinf.2024.106237_bib27","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"Huttner","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2024.106237_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215457","article-title":"Development, qualification, and validation of the Filovirus Animal Nonclinical Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for human serum samples","volume":"14","author":"Rudge","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jinf.2024.106237_bib29","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1056\/NEJMoa1614067","article-title":"Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia","volume":"377","author":"Kennedy","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2024.106237_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj1701","article-title":"A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa","volume":"9","author":"Huttner","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jinf.2024.106237_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1279003","article-title":"Refined innate plasma signature after rVSV\u0394G-ZEBOV-GP immunization is shared among adult cohorts in Europe and North America","volume":"14","author":"Martinez-Murillo","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jinf.2024.106237_bib32","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S1473-3099(17)30313-4","article-title":"Safety and immunogenicity of the rVSV\u2206G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study","volume":"17","author":"Heppner","year":"2017","journal-title":"Lancet Infect Dis"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445324001713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445324001713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:26:58Z","timestamp":1778718418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445324001713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0163445324001713"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2024.106237","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Replication, safety and immunogenicity of the vectored Ebola vaccine rVSV-\u0394G-ZEBOV-GP in a sub-Saharan African paediatric population: A randomised controlled, open-label trial in children aged 1-12 years living in Lambar\u00e9n\u00e9, Gabon","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2024.106237","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106237"}}